Hepatic Tuberculosis Diagnosis and Treatment

Clinical Presentation and Diagnosis

The presence of a liver mass with positive TB testing, such as GeneXpert for M. tuberculosis, strongly suggests hepatic TB involvement, either as isolated hepatic TB or as part of disseminated disease, particularly in patients with constitutional symptoms like weight loss 1
Elevated liver enzymes in patients with liver disease may reflect both underlying liver disease and TB-related hepatic injury, with ALT values up to 5× upper limit of normal expected due to underlying liver disease 2
Screening for hepatitis B and C is recommended, especially in patients with risk factors, to rule out coexistent viral hepatitis 3, 4, 5

The American Thoracic Society recommends initiating 4-drug anti-TB therapy immediately upon diagnosis, consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 4-10 additional months 7
The Centers for Disease Control and Prevention suggests monitoring liver function weekly for two weeks, then biweekly for the first two months, given pre-existing elevated liver enzymes, and stopping rifampin, isoniazid, and pyrazinamide if AST/ALT rises to 5× normal or bilirubin rises 3, 4, 2
In cases of severe hepatic dysfunction, the Infectious Diseases Society of America recommends considering alternative regimens, such as rifampin and ethambutol with a fluoroquinolone for 12-18 months, avoiding isoniazid and pyrazinamide 5
The European Respiratory Society advises against assuming disease progression or initiating corticosteroids for suspected immune-related adverse events without first testing for tuberculosis in patients with constitutional symptoms 6